Deterministic analyses were performed by including in the model the upper and lower values of utility parameters, SCIT unit cost and the effectiveness of the SCIT + ICS in the reduction of the probability of an asthma exacerbation. The proportion of patients with at least one step reduction reported in the treatment arm of the RCT by Zielen et al was included as the maximum value of the probability of medication step-down with SCIT + ICS. An additional analysis was conducted by assigning a zero probability of asthma remission with ICS to account for a pessimistic value. All analyses were conducted in the base case scenario. Probabilistic sensitivity analysis was performed running 1,000 Monte Carlo simulations for non-redundant parameters. Commonly used mathematical distributions were assumed (Table 1).